FDA approves new dosing for Bristol-Myers Squibb's Opdivo

March 6 (Reuters) - Bristol-Myers Squibb Co said on Tuesday the U.S. Food and Drug Administration had approved a new dosing schedule for its drug, Opdivo, across a number of cancers the drug is already approved to treat.

The approval was related to a marketing application for an infused 480 mg dose every four weeks.

Opdivo is already approved to treat a number of cancers such as melanoma. (Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)